IGHE and neoplasm: Lastly, Man et al. went beyond the IgG isotype by examining the in vivo behavior of an IgE‐based anti‐CSPG4 antibody designed to trigger a more robust immune response using, monitored with immunoSPECT.[60] In the absence of FcRn‐mediated recycling, the [111In]In‐IgE was eliminated from the blood of tumor‐bearing mice significantly more quickly than its [111In]In‐IgG counterpart.